2026 ACTRIMS forum Kenneth P Johnson lecture. Autologous hematopoietic stem cell transplantation in multiple sclerosis and other neuroinflammatory conditions: Current evidence and remaining questions

Autologous hematopoietic stem cell transplantation has emerged as a highly effective treatment strategy for selected patients with active relapsing multiple sclerosis and is now being investigated in other neuroinflammatory diseases, including neuromyelitis optica spectrum disorder and stiff person syndrome, among others. Accumulating evidence from observational studies and clinical trials demonstrated sustained suppression of inflammatory disease activity in multiple sclerosis, whereas evidence in other neuroinflammatory diseases remains largely limited to case series. Major professional bodies have endorsed autologous hematopoietic stem cell transplantation as an option for active multiple sclerosis refractory to high-efficacy disease-modifying therapies. Nevertheless, even within the multiple sclerosis field, critical questions remain unresolved. The optimal conditioning regimen and benefit of CD34+ cell selection have not been established. Patient selection criteria require further refinement. Where to place autologous hematopoietic stem cell transplantation among current treatment options remains uncertain. Ongoing randomized trials are expected to substantially advance the evidence base.

Authors

Institutions

Publication Details

Journal
Multiple Sclerosis Journal
Published
2026-11-19
DOI
https://doi.org/10.1177/13524585261502923
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

2026 ACTRIMS forum Kenneth P Johnson lecture. Autologous hematopoietic stem cell transplantation in multiple sclerosis and other neuroinflammatory conditions: Current evidence and remaining questions

Amy C. Kunchok, Jeffrey Allen Cohen, Saira Afzal
Multiple Sclerosis Journal
Multiple Sclerosis Research Studies
article

2026 ACTRIMS forum Kenneth P Johnson lecture. Autologous hematopoietic stem cell transplantation in multiple sclerosis and other neuroinflammatory conditions: Current evidence and remaining questions

Amy C. Kunchok, Jeffrey Allen Cohen, Saira Afzal
article en

Abstract

Autologous hematopoietic stem cell transplantation has emerged as a highly effective treatment strategy for selected patients with active relapsing multiple sclerosis and is now being investigated in other neuroinflammatory diseases, including neuromyelitis optica spectrum disorder and stiff person syndrome, among others. Accumulating evidence from observational studies and clinical trials demonstrated sustained suppression of inflammatory disease activity in multiple sclerosis, whereas evidence in other neuroinflammatory diseases remains largely limited to case series. Major professional bodies have endorsed autologous hematopoietic stem cell transplantation as an option for active multiple sclerosis refractory to high-efficacy disease-modifying therapies. Nevertheless, even within the multiple sclerosis field, critical questions remain unresolved. The optimal conditioning regimen and benefit of CD34+ cell selection have not been established. Patient selection criteria require further refinement. Where to place autologous hematopoietic stem cell transplantation among current treatment options remains uncertain. Ongoing randomized trials are expected to substantially advance the evidence base.

Multiple Sclerosis Journal
Cleveland Clinic (US)
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon